Literature DB >> 7570929

Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery.

L S Jensen1, N Grunnet, F Hanberg-Sørensen, J Jørgensen.   

Abstract

BACKGROUND: The use of white cell (WBC)-reduced blood in elective colorectal surgery appears to reduce the frequency of postoperative infection. The question to be addressed is whether the cost:benefit ratio justifies the recommendation that WBC-reduced blood should be used for all colorectal surgery. STUDY DESIGN AND METHODS: Patients admitted for elective colorectal surgery (n = 197) were randomly assigned to receive transfusion consisting of whole blood or WBC-reduced whole blood. Postoperative complications, postoperative stay, and hospital charges were compared.
RESULTS: Forty-eight patients received WBC-reduced whole blood, 56 received unfiltered whole blood, and 93 received no transfusion. Postoperative infections were significantly higher (p < 0.001) in the group that received unfiltered whole blood. That group also had longer hospital stays: 17 days as compared to stays of 10 and 11 days for the group receiving no transfusion and the group receiving filtered whole blood transfusions, respectively (p < 0.01). The total hospital cost per patient receiving unfiltered whole blood was $12,347, as compared to $7,867 for those who received WBC-reduced whole blood and $7,030 for those who received no transfusion.
CONCLUSION: The use of WBC-reduced whole blood transfusions in elective colorectal surgery significantly reduces the frequency of postoperative infection, the length of hospital stay, and the total hospital charges for patients needing blood transfusion.

Entities:  

Mesh:

Year:  1995        PMID: 7570929     DOI: 10.1046/j.1537-2995.1995.35996029153.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

2.  TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage.

Authors:  Kevin Fleming; Roberta E Redfern; Rebekah L March; Nathan Bobulski; Michael Kuehne; John T Chen; Michael Moront
Journal:  J Extra Corpor Technol       Date:  2017-12

3.  Cost-effectiveness of leucoreduction for prevention of febrile non-haemolytic transfusion reactions.

Authors:  Argirios E Tsantes; Elias Kyriakou; Georgios K Nikolopoulos; Dimitrios Stylos; Marlene Sidhom; Stefanos Bonovas; Panagiota Douramani; Dimitrios Kalantzis; Styliani Kokoris; Serena Valsami; Konstantinos Stamoulis; Marianna Politou; Leontini Foudoulaki-Paparizos
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  National Blood Foundation 2021 Research and Development summit: Discovery, innovation, and challenges in advancing blood and biotherapies.

Authors:  Jerry A Holmberg; Stephen M Henry; Thierry Burnouf; Dana Devine; Susanne Marschner; Thomas C Boothby; Scott R Burger; Stella T Chou; Brian Custer; Neil Blumberg; Donald L Siegel; Steven L Spitalnik
Journal:  Transfusion       Date:  2022-09-28       Impact factor: 3.337

5.  A multi-centre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and healthcare resource use following cardiac surgery: study protocol.

Authors:  Rachel C M Brierley; Katie Pike; Alice Miles; Sarah Wordsworth; Elizabeth A Stokes; Andrew D Mumford; Alan Cohen; Gianni D Angelini; Gavin J Murphy; Chris A Rogers; Barnaby C Reeves
Journal:  Transfus Apher Sci       Date:  2014-03-12       Impact factor: 1.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.